Role and mechanism of molecular hydrogen in the treatment of Parkinson’s diseases.
Fengjiao Wang, Guangjie Zhang, Qingfeng Zhai · Frontiers in neuroscience · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
This narrative review examined the available molecular-hydrogen literature. preclinical studies demonstrate promising results, clinical trials conducted thus far have yielded mixed outcomes, with some trials reporting limited or no therapeutic benefit. Nonetheless, the surgical indications for DBS are relatively stringent, applying only to patients with a disease duration exceeding 5 years who demonstrate a good response to levodopa, and there are specific limitations ( Fenoy and Simpson, 2014 ). These limitations include the risk of postoperative infection and complications related to the hardware, as well as a lack of significant improvement in axial symptoms such as freezing gait and postural imbalance. The reviewed evidence adds support for molecular hydrogen's therapeutic potential across the conditions, mechanisms, or outcomes examined.
What the Findings Mean
H2HUBB reviewed this publication as a synthesis of molecular-hydrogen research and summarizes the outcomes emphasized by the authors. preclinical studies demonstrate promising results, clinical trials conducted thus far have yielded mixed outcomes, with some trials reporting limited or no therapeutic benefit.
What the Researchers Studied
The authors reviewed role and mechanism of molecular hydrogen in the treatment of Parkinson's diseases.
What Effects Did Molecular Hydrogen Have?
Preclinical studies demonstrate promising results, clinical trials conducted thus far have yielded mixed outcomes, with some trials reporting limited or no therapeutic benefit. In recent years, molecular hydrogen has been recognized for its potential neuroprotective effects, attributed to its selective antioxidant and anti-inflammatory properties.
Why These Findings Matter
The reviewed evidence adds support for molecular hydrogen's therapeutic potential across the conditions, mechanisms, or outcomes examined.
How Strong Is This Evidence?
This is review or synthesis evidence (narrative review).
Technical Study Details
H2HUBB classifies this publication as narrative review with review or synthesis evidence. The study used a narrative review. The hydrogen delivery method was hydrogen-rich water.
Limitations and Safety
Reported limitations: Nonetheless, the surgical indications for DBS are relatively stringent, applying only to patients with a disease duration exceeding 5 years who demonstrate a good response to levodopa, and there are specific limitations ( Fenoy and Simpson, 2014 ). These limitations include the risk of postoperative infection and complications related to the hardware, as well as a lack of significant improvement in axial symptoms such as freezing gait and postural imbalance.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.